The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen's RenLite platform.

EVERSANA’s senior vice president of innovation discusses how the technology has been implemented in various areas of the ...

In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, speaks about the broader ...

The two companies will use Astrana’s technology offerings to improve access. Health insurer Anthem Blue Cross and physicians’ ...

DSP-5336 targets the menin and mixed-lineage leukemia protein interaction, crucial in various biological processes, including ...

In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, discusses how their AI/ML ...

Clearance of the New Drug Application for ART25.12 allows Artelo to begin a Phase I study for the drug in ...

The global president of endomechanical and energy for Johnson & Johnson MedTech discusses the need for multidisciplinary care ...

Congress and our nation’s public health officials should take the current moment to self-reflect and resolve challenges with ...

The CEO of Revelation Pharma discusses how compounding pharmacies may help solve the ongoing issue with drug shortages.

JAMA study aims to discover how weight loss differs between patients receiving tirzepatide compared with semaglutide among a ...

Amylyx Pharmaceuticals has acquired Eiger BioPharmaceuticals’ avexitide, a Phase III-ready GLP-1 receptor antagonist being ...